[Evaluation of latamoxef in the treatment of infections of newborn infants].
The usefulness of latamoxef (LMOX) in the treatment of newborn infants was investigated. The results that were obtained are summarized below. LMOX was injected intravenously in a dose of about 20 mg/kg, and 30 minutes later the concentration of the drug in the serum was determined. In a very low-birth-weight infant, weighing only 978 g at the time of birth, the serum concentration on the 3rd day after birth was 94 micrograms/ml, while it was found to be 100 micrograms/ml when the dosing and determination were performed on the 37th day after birth. Another premature infant weighed 1,980 g at birth, and on the 8th day of life the serum concentration was 73 micrograms/ml. The half-lives of LMOX in these 3 administrations were 4.74, 3.95 and 3.20 hours, respectively. LMOX was administered by intravenous injection to 4 patients diagnosed as having 6 diseases (2 patients each had both septicemia and a urinary tract infection; 1 patient had pneumonia; 1 patient had septicemia). Each dose ranged from about 15 to 25 mg/kg, and 3 doses were administered daily (in 1 patient, 4 doses were given over a 2-day period). The evaluation of the clinical results for each disease case showed 4 excellent cases and 2 poor cases. The 2 poor cases consisted of 1 case of pneumonia caused by S. aureus, and 1 case of a mixed urinary tract infection caused by E. coli and S. faecalis.(ABSTRACT TRUNCATED AT 250 WORDS)
D001424:Bacterial Infections / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D008297:Male; D009070:Moxalactam / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D009070:Moxalactam